Table 5 The baseline characteristics of training and validation set
From: Risk factors for metastasis and poor prognosis of Ewing sarcoma: a population based study
Characteristic | All patients (N = 1160) Number (%) | Traning set (N = 570, 49.1%) Number (%) | Validation set (N = 590, 50.9%) Number (%) | p value |
|---|---|---|---|---|
Age (years) | 0.349 | |||
≤ 10 | 242 (20.9%) | 117 (20.5%) | 125 (21.2%) | |
11–20 | 571 (49.2%) | 288 (50.5%) | 283 (48.0%) | |
21–30 | 206 (17.8%) | 105 (18.4%) | 101 (17.1%) | |
31–49 | 101 (8.7%) | 46 (8.1%) | 55 (9.3%) | |
≥ 50 | 40 (3.4%) | 14 (2.5%) | 26 (4.4%) | |
Gender | 0.084 | |||
Male | 733 (63.2%) | 346 (60.7%) | 387 (65.6%) | |
Female | 427 (36.8%) | 224 (39.3%) | 203 (34.4%) | |
Race | 0.727 | |||
White | 1041 (89.7%) | 511 (89.6%) | 530 (89.8%) | |
Black | 30 (2.6%) | 13 (2.3%) | 17 (2.9%) | |
Other | 89 (7.7%) | 46 (8.1%) | 43 (7.3%) | |
Primary site | 0.384 | |||
Limb | 519 (44.7%) | 254 (44.6%) | 265 (44.9%) | |
Cranial | 66 (5.7%) | 32 (5.6%) | 34 (5.8%) | |
Spine | 88 (7.6%) | 37 (6.5%) | 51 (8.6%) | |
Thoracic | 173 (14.9%) | 95 (16.7%) | 78 (13.2%) | |
Pelvic | 314 (27.1%) | 152 (26.7%) | 162 (27.5%) | |
Tumor size (cm) | 0.296 | |||
< 5 | 221 (19.1%) | 119 (20.9%) | 102 (17.3%) | |
5–8 | 371 (32.0%) | 179 (31.4%) | 192 (32.5%) | |
> 8 | 568 (49.0%) | 272 (47.7%) | 296 (50.2%) | |
Tumor extent | 0.985 | |||
Localized | 311 (26.8%) | 153 (26.8%) | 158 (26.8%) | |
Regional | 533 (45.9%) | 263 (46.1%) | 270 (45.8%) | |
Metastatic | 316 (27.2%) | 154 (27.0%) | 162 (27.5%) | |
Cancer-directed surgery | 0.651 | |||
No | 390 (33.6%) | 188 (33.0%) | 202 (34.2%) | |
Yes | 770 (66.4%) | 382 (67.0%) | 388 (65.8%) | |
Radiation | 0.636 | |||
No | 584 (50.3%) | 291 (51.1%) | 293 (49.7%) | |
Yes | 576 (49.7%) | 279 (48.9%) | 297 (50.3%) | |
Chemotherapy | 0.032* | |||
No | 40 (3.4%) | 13 (2.3%) | 27 (4.6%) | |
Yes | 1120 (96.6%) | 557 (97.7%) | 563 (95.4%) | |